home / stock / oryzf / oryzf quote
Last: | $1.41 |
---|---|
Change Percent: | 0.0% |
Open: | $1.41 |
Close: | $1.41 |
High: | $1.41 |
Low: | $1.41 |
Volume: | 300 |
Last Trade Date Time: | 04/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.41 | $1.41 | $1.41 | $1.41 | $1.41 | 300 | 04-16-2024 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 300 | 03-13-2024 |
$2 | $2.25 | $2 | $2.25 | $2 | 12,000 | 02-07-2024 |
$1.8 | $2.1 | $1.8 | $2.1 | $1.8 | 5,000 | 01-09-2024 |
$1.77 | $2.26 | $1.77 | $2.26 | $1.77 | 5,000 | 01-08-2024 |
$1.7 | $1.7 | $1.7 | $1.7 | $1.7 | 2,000 | 11-24-2023 |
$2.22 | $2.22 | $2.22 | $2.22 | $2.22 | 750 | 09-05-2023 |
$2.45 | $2.45 | $2.45 | $2.45 | $2.45 | 245 | 05-31-2023 |
$2.45 | $2.45 | $2.45 | $2.45 | $2.45 | 204 | 03-29-2023 |
$2.45 | $2.45 | $2.45 | $2.45 | $2.45 | 750 | 03-14-2023 |
$2.6 | $2.6 | $2.6 | $2.6 | $2.6 | 100 | 04-27-2022 |
$2.77 | $2.77 | $2.77 | $2.77 | $2.77 | 100 | 03-08-2022 |
$2.77 | $2.77 | $2.77 | $2.77 | $2.77 | 100 | 01-24-2022 |
$4.13 | $4.13 | $4.13 | $4.13 | $4.13 | 5,000 | 07-26-2021 |
$4.36 | $4.36 | $4.36 | $4.36 | $4.36 | 100 | 07-12-2021 |
$4.67 | $4.67 | $4.67 | $4.67 | $4.67 | 200 | 06-28-2021 |
$4.77 | $4.77 | $4.77 | $4.77 | $4.77 | 300 | 06-18-2021 |
$4.18 | $4.18 | $4.18 | $4.18 | $4.18 | 4,000 | 05-06-2021 |
$4.15 | $4.15 | $4.15 | $4.15 | $4.15 | 300 | 05-05-2021 |
$4.6 | $4.6 | $4.6 | $4.6 | $4.6 | 1,000 | 03-11-2021 |
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
Bio-Equity Europe 2024 Asebio Investor Day 2024 RSC Hot Topics: Covalent Drug Discovery Foro Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutica...
Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial in BPD Strengthening the IP position in CNS w...
Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage bioph...